Herantis Pharma Oyj (HRPMF) Stock

About Herantis Pharma Oyj

Herantis Pharma Oyj, a biotechnology enterprise, specializes in creating disease-modifying therapies for Parkinson's disease (PD) that harness Cerebral Dopamine Neurotrophic Factor (CDNF). Central to its developmental efforts is HER-096, a sophisticated, compact, synthetic chemical peptidomimetic originating from the active parent molecule. This preclinical xCDNF candidate is currently being investigated for its therapeutic promise in PD and other neurodegenerative conditions. Additionally, the firm is advancing recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is presently undergoing Phase I clinical evaluation in individuals afflicted with Parkinson's. Founded in 2008, Herantis Pharma Oyj maintains its corporate headquarters in Espoo, Finland.

Herantis Pharma Oyj is headquartered in FI.

Herantis Pharma Oyj (HRPMF) stock trades at $3.51 with a market capitalization of $59.47M. The stock is valued at a negative price-to-earnings (P/E) ratio of -6.09, reflecting a net loss over the last twelve months, a negative price-to-book of -23.48, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.51 and $3.51, and currently trades at or near its 52-week high.

On profitability, Herantis Pharma Oyj generates return on capital employed of -364.24%.

Official website: www.herantis.com